Arvanil

Overview

Arvanil (N-Vanillylarachidonamide) is a mixed agonist of CB1 and TRPV1 receptors. Arvanil downregulates CD25 , HLA-DR , CD134/OX40 , blocks G1/S phase transition, and induces phosphorylation of Akt . Arvanil does not induce apoptosis in cells. Arvanil inhibits lymphocyte activation and ameliorates autoimmune encephalomyelitis. Arvanil can be used in research related to Huntington's disease, vomiting, and multiple sclerosis.

Application

Products | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Autoimmune Disease | Products > Disease Areas > CNS Infection | Products > Disease Areas > Huntington's Disease | Products > Disease Areas > Experimental Autoimmune Encephalomyelitis | Products > Disease Areas > Multiple Sclerosis | Products > Signaling Pathways > Membrane Transporter/Ion Channel | Products > Signaling Pathways > Neuronal Signaling | Products > Signaling Pathways > GPCR/G Protein | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Research Areas > Neurological Disease | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > Akt | Products > Signaling Pathways > Orexin Receptor (OX Receptor) | Products > Signaling Pathways > TRP Channel | Products > Signaling Pathways > Cannabinoid Receptor | Products > Signaling Pathways > CD74

Product Information

• Catalog No.: HY-103333
• CAS No.: 128007-31-8
• Molecular Formula: C28H41NO3
• Molecular Weight: 439.63
• Purity: 99.1%
• Storage: Solution, -20°C, 2 years
• Availability: In-stock

Source

Original product source